Biopharmaceutical CMO and CRO Market (By Service: Contract Manufacturing and Contract Research; By Source: Mammalian and Non-Mammalian; By Product Type: Biologics and Biosimilars) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 - 2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Source Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Biopharmaceutical CMO and CRO Market, By Product

7.1. Biopharmaceutical CMO and CRO Market, by Product Type, 2023-2032

7.1.1. Biologics (Vaccines, Monoclonal antibodies (MABs), Recombinant Proteins, Others)

7.1.1.1. Market Revenue and Forecast (2021-2032)

7.1.2. Biosimilars

7.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 8. Global Biopharmaceutical CMO and CRO Market, By Service

8.1. Biopharmaceutical CMO and CRO Market, by Service, 2023-2032

8.1.1. Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC studies, Packaging)

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Contract Research (Inflammation & Immunology, Cardiology, Oncology, Neuroscience, Others)

8.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Biopharmaceutical CMO and CRO Market, By Source 

9.1. Biopharmaceutical CMO and CRO Market, by Source, 2023-2032

9.1.1. Mammalian

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Non-Mammalian

9.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Biopharmaceutical CMO and CRO Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2021-2032)

10.1.2. Market Revenue and Forecast, by Service (2021-2032)

10.1.3. Market Revenue and Forecast, by Source (2021-2032)

10.1.4. U.S.

10.1.4.1. Market Revenue and Forecast, by Product (2021-2032)

10.1.4.2. Market Revenue and Forecast, by Service (2021-2032)

10.1.4.3. Market Revenue and Forecast, by Source (2021-2032)

10.1.5. Rest of North America

10.1.5.1. Market Revenue and Forecast, by Product (2021-2032)

10.1.5.2. Market Revenue and Forecast, by Service (2021-2032)

10.1.5.3. Market Revenue and Forecast, by Source (2021-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2021-2032)

10.2.2. Market Revenue and Forecast, by Service (2021-2032)

10.2.3. Market Revenue and Forecast, by Source (2021-2032)

10.2.4. UK

10.2.4.1. Market Revenue and Forecast, by Product (2021-2032)

10.2.4.2. Market Revenue and Forecast, by Service (2021-2032)

10.2.4.3. Market Revenue and Forecast, by Source (2021-2032)

10.2.5. Germany

10.2.5.1. Market Revenue and Forecast, by Product (2021-2032)

10.2.5.2. Market Revenue and Forecast, by Service (2021-2032)

10.2.5.3. Market Revenue and Forecast, by Source (2021-2032)

10.2.6. France

10.2.6.1. Market Revenue and Forecast, by Product (2021-2032)

10.2.6.2. Market Revenue and Forecast, by Service (2021-2032)

10.2.6.3. Market Revenue and Forecast, by Source (2021-2032)

10.2.7. Rest of Europe

10.2.7.1. Market Revenue and Forecast, by Product (2021-2032)

10.2.7.2. Market Revenue and Forecast, by Service (2021-2032)

10.2.7.3. Market Revenue and Forecast, by Source (2021-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2021-2032)

10.3.2. Market Revenue and Forecast, by Service (2021-2032)

10.3.3. Market Revenue and Forecast, by Source (2021-2032)

10.3.4. India

10.3.4.1. Market Revenue and Forecast, by Product (2021-2032)

10.3.4.2. Market Revenue and Forecast, by Service (2021-2032)

10.3.4.3. Market Revenue and Forecast, by Source (2021-2032)

10.3.5. China

10.3.5.1. Market Revenue and Forecast, by Product (2021-2032)

10.3.5.2. Market Revenue and Forecast, by Service (2021-2032)

10.3.5.3. Market Revenue and Forecast, by Source (2021-2032)

10.3.6. Japan

10.3.6.1. Market Revenue and Forecast, by Product (2021-2032)

10.3.6.2. Market Revenue and Forecast, by Service (2021-2032)

10.3.6.3. Market Revenue and Forecast, by Source (2021-2032)

10.3.7. Rest of APAC

10.3.7.1. Market Revenue and Forecast, by Product (2021-2032)

10.3.7.2. Market Revenue and Forecast, by Service (2021-2032)

10.3.7.3. Market Revenue and Forecast, by Source (2021-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2021-2032)

10.4.2. Market Revenue and Forecast, by Service (2021-2032)

10.4.3. Market Revenue and Forecast, by Source (2021-2032)

10.4.4. GCC

10.4.4.1. Market Revenue and Forecast, by Product (2021-2032)

10.4.4.2. Market Revenue and Forecast, by Service (2021-2032)

10.4.4.3. Market Revenue and Forecast, by Source (2021-2032)

10.4.5. North Africa

10.4.5.1. Market Revenue and Forecast, by Product (2021-2032)

10.4.5.2. Market Revenue and Forecast, by Service (2021-2032)

10.4.5.3. Market Revenue and Forecast, by Source (2021-2032)

10.4.6. South Africa

10.4.6.1. Market Revenue and Forecast, by Product (2021-2032)

10.4.6.2. Market Revenue and Forecast, by Service (2021-2032)

10.4.6.3. Market Revenue and Forecast, by Source (2021-2032)

10.4.7. Rest of MEA

10.4.7.1. Market Revenue and Forecast, by Product (2021-2032)

10.4.7.2. Market Revenue and Forecast, by Service (2021-2032)

10.4.7.3. Market Revenue and Forecast, by Source (2021-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2021-2032)

10.5.2. Market Revenue and Forecast, by Service (2021-2032)

10.5.3. Market Revenue and Forecast, by Source (2021-2032)

10.5.4. Brazil

10.5.4.1. Market Revenue and Forecast, by Product (2021-2032)

10.5.4.2. Market Revenue and Forecast, by Service (2021-2032)

10.5.4.3. Market Revenue and Forecast, by Source (2021-2032)

10.5.5. Rest of LATAM

10.5.5.1. Market Revenue and Forecast, by Product (2021-2032)

10.5.5.2. Market Revenue and Forecast, by Service (2021-2032)

10.5.5.3. Market Revenue and Forecast, by Source (2021-2032)

Chapter 11. Company Profiles

11.1. Lonza

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. JRS Pharma

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Samsung Biologics

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. CMC Biologics

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. TOYOBO Co. Ltd.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. RentschlerBiotechnologie

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. FUJIFILM Diosynth Biotechnologies

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. WuXi Biologics

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Patheon

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. BoehringerIngelheim

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

11.11. PRA Health Sciences

11.11.1. Company Overview

11.11.2. Product Offerings

11.11.3. Financial Performance

11.11.4. Recent Initiatives

11.12. LabCorp

11.12.1. Company Overview

11.12.2. Product Offerings

11.12.3. Financial Performance

11.12.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample